^
Association details:
| Biomarker: | FGFR3 expression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + rogaratinib (BAY 1163877) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.
Published date:
05/19/2021
Excerpt:
First-line treatment with the RP2D of R+A achieved favorable clinical efficacy and tolerability in pts with cisplatin-ineligible, metastatic UC characterized by high FGFR1/3 mRNA expression and generally low/negative PD-L1 expression.
DOI:
10.1200/JCO.2021.39.15_suppl.4521
Trial ID:
